160 related articles for article (PubMed ID: 28428278)
1. Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma.
Jariwala N; Rajasekaran D; Mendoza RG; Shen XN; Siddiq A; Akiel MA; Robertson CL; Subler MA; Windle JJ; Fisher PB; Sanyal AJ; Sarkar D
Cancer Res; 2017 Jun; 77(12):3306-3316. PubMed ID: 28428278
[TBL] [Abstract][Full Text] [Related]
2. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
3. Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL).
Rajasekaran D; Jariwala N; Mendoza RG; Robertson CL; Akiel MA; Dozmorov M; Fisher PB; Sarkar D
J Biol Chem; 2016 May; 291(20):10736-46. PubMed ID: 26997225
[TBL] [Abstract][Full Text] [Related]
4. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma.
Yoo BK; Santhekadur PK; Gredler R; Chen D; Emdad L; Bhutia S; Pannell L; Fisher PB; Sarkar D
Hepatology; 2011 May; 53(5):1538-48. PubMed ID: 21520169
[TBL] [Abstract][Full Text] [Related]
5. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
6. Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma.
Wolf B; Krieg K; Falk C; Breuhahn K; Keppeler H; Biedermann T; Schmid E; Warmann S; Fuchs J; Vetter S; Thiele D; Nieser M; Avci-Adali M; Skokowa Y; Schöls L; Hauser S; Ringelhan M; Yevsa T; Heikenwalder M; Kossatz-Boehlert U
Cancer Res; 2016 Sep; 76(18):5550-61. PubMed ID: 27488521
[TBL] [Abstract][Full Text] [Related]
7. Loss of the methylarginine reader function of SND1 confers resistance to hepatocellular carcinoma.
Wright T; Wang Y; Stratton SA; Sebastian M; Liu B; Johnson DG; Bedford MT
Biochem J; 2023 Nov; 480(22):1805-1816. PubMed ID: 37905668
[TBL] [Abstract][Full Text] [Related]
8. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
[TBL] [Abstract][Full Text] [Related]
9. OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways.
Li H; Zhang J; Lee MJ; Yu GR; Han X; Kim DG
Oncotarget; 2017 Mar; 8(11):18129-18144. PubMed ID: 28184024
[TBL] [Abstract][Full Text] [Related]
10. IGFBP7 Deletion Promotes Hepatocellular Carcinoma.
Akiel M; Guo C; Li X; Rajasekaran D; Mendoza RG; Robertson CL; Jariwala N; Yuan F; Subler MA; Windle J; Garcia DK; Lai Z; Chen HH; Chen Y; Giashuddin S; Fisher PB; Wang XY; Sarkar D
Cancer Res; 2017 Aug; 77(15):4014-4025. PubMed ID: 28619711
[TBL] [Abstract][Full Text] [Related]
11. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
12. (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression.
Nguyen CB; Kotturi H; Waris G; Mohammed A; Chandrakesan P; May R; Sureban S; Weygant N; Qu D; Rao CV; Dhanasekaran DN; Bronze MS; Houchen CW; Ali N
Cancer Res; 2016 Aug; 76(16):4887-96. PubMed ID: 27287718
[TBL] [Abstract][Full Text] [Related]
13. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221.
Santhekadur PK; Das SK; Gredler R; Chen D; Srivastava J; Robertson C; Baldwin AS; Fisher PB; Sarkar D
J Biol Chem; 2012 Apr; 287(17):13952-8. PubMed ID: 22396537
[TBL] [Abstract][Full Text] [Related]
14. IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition
Mitra A; Yan J; Xia X; Zhou S; Chen J; Mishra L; Li S
Hepatology; 2017 Apr; 65(4):1222-1236. PubMed ID: 27863449
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
18. SND1 overexpression deregulates cholesterol homeostasis in hepatocellular carcinoma.
Navarro-Imaz H; Rueda Y; Fresnedo O
Biochim Biophys Acta; 2016 Sep; 1861(9 Pt A):988-996. PubMed ID: 27238764
[TBL] [Abstract][Full Text] [Related]
19. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
[TBL] [Abstract][Full Text] [Related]
20. Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure.
Vandewynckel YP; Laukens D; Devisscher L; Paridaens A; Bogaerts E; Verhelst X; Van den Bussche A; Raevens S; Van Steenkiste C; Van Troys M; Ampe C; Descamps B; Vanhove C; Govaere O; Geerts A; Van Vlierberghe H
Oncotarget; 2015 Sep; 6(29):28011-25. PubMed ID: 26293671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
